Wockhardt is the top gainer on the BSE; as soon as the market opened for trading, from its close of Rs.1396.75, the stock opened 1.3% higher and within minutes hit a new high and its 10% UC of the day at Rs.1536.40.

The stock hit the roof after Wockhardt’s novel proprietary antibiotic, Zaynich, targeted towards multi-drug resistant Gram-negative infections enabled a US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme-drug resistant Gram negative pathogens.

This drug is currently nearing completion of Phase III study which would support its registration/marketing authorization globally.

Earlier, multiple Phase I studies including clinical pharmacology studies with zidebactam/cefepime were conducted in US. ZaynichTM (Zidebactam/Cefepime) is also undergoing a clinical study in India for the treatment of carbapenem-resistant infections.

Zaynich was given compassionate use approval by FDA in the form of individual patient-specific expanded-access IND.

Wockhardt stated that till date, 45 patients in the US have benefitted under compassionate use of Zidebactam/Cefepime who were suffering from range of life-threatening Gram negative infections.